The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate ...

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.

NEW YORK – QuidelOrtho announced Monday an integration deal making fecal biomarker testing from Bühlmann Laboratories available on QuidelOrtho's Vitros system. The Bühlmann fecal tests detect ...

Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing ...

NEW YORK – VieCure said Thursday that it has entered a strategic partnership with cancer genomic testing firm Guardant Health to embed Guardant's menu of precision oncology tests into the VieCure Halo ...

The San Diego-based firm said that it is transitioning beyond laboratory-developed tests and expanding access to its tests for the detection of early-stage cancers.

The firms will distribute NowDx's First to Know test to more than 15 organizations nationwide, including LGBTQ+ health centers, HIV/AIDS care providers, and safety-net clinics.

The UK government said that it plans this year to repeal regulations specific to COVID-19 tests as part of the alignment with EU Common Specifications.

The test is covered for serial use in patients with colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period.